Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD0171
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AZD0171 (INN: Falbikitug) is a humanized monoclonal antibody of the IgG1 subclass developed by AstraZeneca. It targets leukemia inhibitory factor (LIF), binding with high affinity to LIF and blocking its signaling through the LIF receptor. This mechanism modulates tumor-associated macrophages and inhibits cancer stem cell function, promoting antitumor inflammation within the tumor microenvironment. Preclinical studies demonstrated efficacy in murine cancer models and patient-derived xenografts. Clinical trials have evaluated AZD0171 as monotherapy and in combination with durvalumab (an anti–PD-L1 antibody) plus standard chemotherapy for advanced solid tumors such as pancreatic ductal adenocarcinoma and non-small-cell lung cancer[2][5][6]. The drug is administered intravenously.
- Other names
- FalbikitugMSC-1MSC1MSC 1
02
Targets
LIF (Leukemia inhibitory factor)
Beyond the preview
Go deeper on AZD0171.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD0171.